Bambusa Therapeutics announced October 29 that it priced an enlarged initial public offering of 10,555,555 common shares at $16 each.
The company expects gross proceeds of approximately $168.9 million before underwriting discounts, commissions and other offering expenses. All shares in the offering are being sold by Bambusa.
Trading on the Nasdaq Global Select Market is expected to begin October 30 under the symbol BBTX. The offering is expected to close November 2, subject to customary conditions. Neither milestone had occurred when the pricing announcement was issued.
Bambusa granted the underwriters a 30-day option to buy up to 1,583,333 additional shares at the offering price, less underwriting discounts and commissions.
BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are the joint book-running managers. The company said the registration statements became effective October 29.
Bambusa develops experimental antibodies for immunology and inflammatory diseases. The financing announcement does not establish that its drug candidates are approved or effective.
Sources: Bambusa October 29 pricing announcement via PR Newswire: https://www.tradingview.com/news/prnewswire:ae587ba4f84f9:0-bambusa-therapeutics-announces-pricing-of-upsized-initial-public-offering/